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Abstract
Background: The most common bariatric surgery, Roux-en-Y gastric bypass, leads to
glycemia normalization in most patients long before there is any appreciable weight
loss. This effect is too large to be attributed purely to caloric restriction, so a number of
other mechanisms have been proposed. The most popular hypothesis is enhanced
production of an incretin, active glucagon-like peptide-1 (GLP-1), in the lower intestine.
We therefore set out to test this hypothesis with a model which is simple enough to be
robust and credible.
Method: Our method involves (1) setting up a set of time-dependent equations for
the concentrations of the most relevant species, (2) considering an “adiabatic” (or
quasi-equilibrium) state in which the concentrations are slowly varying compared to
reaction rates (and which in the present case is a postprandial state), and (3) solving for
the dependent concentrations (of e.g. insulin and glucose) as an independent
concentration (of e.g. GLP-1) is varied.
Results: Even in the most favorable scenario, with maximal values for (i) the increase in
active GLP-1 concentration and (ii) the effect of GLP-1 on insulin production,
enhancement of GLP-1 alone cannot account for the observations. I.e., the largest
possible decrease in glucose predicted by the model is smaller than reported
decreases, and the model predicts no decrease whatsoever in glucose×insulin, in
contrast to large observed decreases in homeostatic model assessment insulin
resistance (HOMA-IR). On the other hand, both effects can be accounted for if the
surgery leads to a substantial increase in some substance that opens an alternative
insulin-independent pathway for glucose transport into muscle cells, which perhaps
uses the same intracellular pool of GLUT-4 that is employed in an established
insulin-independent pathway stimulated by muscle contraction during exercise.
Conclusions: Glycemia normalization following Roux-en-Y gastric bypass is
undoubtedly caused by a variety of mechanisms, which may include caloric restriction,
enhanced GLP-1, and perhaps others proposed in earlier papers on this subject.
However, the present results suggest that another possible mechanism should be
added to the list of candidates: enhanced production in the lower intestine of a
substance which opens an alternative insulin-independent pathway for glucose
transport.
© 2013 Allen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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Background
Type 2 diabetes
Type 2 diabetes (T2D) has reached epidemic proportions worldwide. In 2011, an esti-
mated 366million people had diabetes, and this number is predicted to rise to 522million
by 2030 [1]. The medical and socioeconomic burdens of the disease and the strains
imposed on health-care systems arise from the devastating associated macro- and micro-
vascular complications such as nephropathy, hypertension, retinopathy, cardiovascular
diseases, and amputations, which make diabetes a major cause of both morbidity and
mortality. Cardiovascular morbidity, for example, is 2 to 4 times greater in patients with
T2D than in non-diabetic people [2].
T2D develops in adulthood and is generally considered to be a condition marked by
insulin resistance and loss of function of insulin-secreting pancreatic beta cells. The exact
etiology of T2D remains largely unknown. So far, over 60 genes have been associated
with an increased risk for T2D [3]. However, even when pooled, these genes only account
for 5-10% of disease risk [4]. Currently, it is widely recognized that obesity is the major
independent risk factor for the development of T2D, and that the rise in T2D prevalence
worldwide is driven by an increasing frequency of obesity, which, in turn, is driven by
a combination of genetic predisposition and interactions with obesogenic environments
including high intake of energy-dense food and physical inactivity [5]. Obesity-associated
T2D development (diabesity) is due to the excess fat that affects many organs that are
involved in glucose homeostasis, including liver and pancreas.
There is a general consensus today that T2D is a lifetime disease and that a medical
cure for patients suffering fromT2D does not exist. Current medical management of T2D
leaves much to be desired, requiring constant vigilance from both patients and physi-
cians. At best, the available medications, when combined with diet and physical activity,
are targeted to lower blood glucose and decrease the peripheral insulin resistance asso-
ciated with T2D. However, medical treatment has had limited success maintaining safe
blood glucose levels in patients, as evidenced, for example, by high numbers of diabetic
amputations and new onset blindness [6,7]. With minimal success of medical treatment,
there is an urgent need for a more permanent cure for the disease that has debilitated
so many patients. Currently the only hope for a T2D “cure” (or at least long term remis-
sion) is bariatric surgery in very obese patients, which has opened new horizons for
understanding the pathophysiology of T2D, and perhaps also hope for new therapies.
Bariatric surgery
Also called metabolic surgery, this is a form of gastrointestinal surgery that aims at reduc-
ing the amount of food intake and/or the absorption of nutrients at the intestinal level.
It is, to date, the most successful intervention for the treatment of obesity. In most cases,
bariatric surgery achieves a significant and sustained weight loss ranging from 12% to 39%
of presurgical body weight or 40-71% excess weight loss (EWL) [8,9].
There exist a dozen bariatric surgery procedures, which fall into the following cate-
gories: (i) Restrictive procedure: the aim is to limit the amount of food intake by reducing
the size of the stomach. (ii) Malabsorptive procedure: the aim is to limit the absorption
of food in the intestinal tract by bypassing a portion of the small intestine to vary-
ing degrees. (iii) Combination of both restriction and malabsorption. The four standard
bariatric surgery procedures that are currently accepted for weight loss in obese patients
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are: (1) adjustable gastric banding (AGB), which is solely restrictive; (2) Roux-en-Y gas-
tric bypass (RYGB), which has both restrictive and malabsorptive components; (3) sleeve
gastrectomy, which is another solely restrictive procedure used for treatment of morbid
obesity; (4) biliopancreatic diversion with duodenal switch (BPDDS), which is a more rad-
ical restrictive and malabsorptive procedure [10,11]. Among the four currently accepted
procedures, Roux-en-Y gastric bypass (RYGB), where the majority of the stomach and
duodenum are bypassed because the stomach is reduced to a small proximal pouch and
is then anastomosed to the jejunum [12], and laparoscopic adjustable gastric banding
(LAGB), where the stomach is reduced to a small pouch by encircling the upper part of
the stomach with a band-like fluid-filled tube, are the most frequently performed world-
wide. Sleeve gastrectomy, where the stomach is reduced by 85% by excising the greater
curvature and reconstructing a tubularized stomach conduit, is gaining popularity and is
widely used for severely obese patients who are high-risk surgery candidates [13].
Bariatric surgery was initially used to induce weight loss in morbidly obese patients.
However, it turned out that it also results in an improvement in many obesity related
comorbidities including T2D [14]. Today, although curing diabetes cannot yet be consid-
ered a goal of bariatric surgery, it may be considered a serendipitous benefit.
Bariatric surgery induces long-term remission of type 2 diabetes
The last two decades have witnessed the emergence of bariatric surgery as a powerful
intervention that, in addition to inducing the drastic and sustained weight loss for which
it was initially designed, leads to long-term remission of T2D, decreasing the progres-
sion and potentially reversing the effects of diabetes in 40-80% of morbidly obese patients
(BMI> 40 kg/m2, or BMI> 35 kg/m2 with comorbidities) [15-20]. The first report show-
ing a serendipitous improvement or remission of hyperglycemia after gastrectomy was
published in the 1950s [21]. However, it was in 1995 that Walter Pories and his colleagues
described in a seminal paper a sustained improvement in glycemia control for up to 14
years after gastric bypass surgery in morbidly obese patients with T2D [22]. This aston-
ishingly beneficial effect of bariatric surgery on glucose homeostasis was confirmed by
numerous subsequent studies in both humans and animal models [16,18].
It is well documented that weight loss, whatever the means used, improves glycemic
control in obese or overweight diabetics, and it is therefore easy to attribute the remark-
able return to euglycemia after bariatric surgery to weight loss. However, while weight loss
certainly plays a major role in inducing improved glucose homeostasis after metabolic
surgery, the striking glycemia normalization after bariatric surgery, as reported by many
investigators, is achieved within a few days post-operation, long before any significant
weight loss has taken place [22], and many obese diabetic patients are able to decrease,
or discontinue, insulin and oral hypoglycemics just days after undergoing surgery [23].
Moreover, there is evidence that even non-obese patients with T2D [24-27] and animal
models [28] experience similar anti-diabetic effects without significant weight loss.
This rapid time course and disproportional degree of T2D cure, or at least long-
term remission, strongly suggests that resolution of T2D is driven by mechanisms that
are surgery-specific and independent of weight loss. Given the immense positive con-
sequences that resolution of T2D will have on the patients’ quality of life and on the
diabetes-related expenditure for the patients and for the health-care systems [29], interest
in the mechanisms that underlie the remission of T2D has spurred huge interest from the
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scientific community during the last decade. In fact, understanding the effects of bariatric
surgery on T2Dwould provide important insights into the pathogenesis of type 2 diabetes
and allow the development of new procedures, devices, and drugs both for obese and
non-obese patients. It is hoped that pharmaceutical mimetics of the underlying mecha-
nisms would potentially offer powerful new medicines for the treatment of T2D without
invasive and risky surgery.
Mechanisms underlying immediate and long-term remission
Despite immense efforts worldwide, the mechanisms behind the glycemic normalization
after metabolic surgery remain elusive. It was initially thought that the observed remis-
sion of T2D is the obvious result of weight loss, as significant weight loss improves insulin
resistance and contributes to diabetes management. However, this hypothesis is chal-
lenged by the very rapid adjustment of glycemia reported in many studies, long before
any significant weight loss is achieved. Moreover, the positive effect of surgery on glucose
tolerance exceeds that achieved after equivalent weight loss via diet and exercise [30] or
after conventional medical therapy [18]. Several plausible hypotheses can be articulated
to explain the rapid, weight-independent glycemic effects of bariatric surgery, and none
of them necessarily precludes the others. In fact, it is likely that the beneficial effect is the
result of the involvement of multiple pathways that involve signals to and from different
metabolism-related organs including the brain, adipose tissue, pancreas, gastrointestinal
tract, liver, kidney, skeletal muscle, and perhaps others. The main suggested hypotheses
are listed below. Since there is a vast literature on the effects of bariatric surgery, it should
be emphasized that the papers cited here are primarily a representative sample from pub-
lished work that features the very short-term effects of one specific procedure, namely
RYGB.
Caloric restrictionhypothesis
According to this hypothesis, the remission of T2D after metabolic surgery is due to post-
operative caloric restriction. The ability of acute caloric restriction to transiently improve
T2D is well known [31,32]. (See, e.g., Figure three of Ref. [32] for 3-7 days of very low
calorie dieting.) According to this model, by the time the patients are allowed ad libitum
eating, they begin to experience the insulin-sensitizing effects of dynamic weight loss
from the surgery. Though prima facie reasonable, this hypothesis fails to explain why the
remission of T2D is far faster after RYGB than AGB, while they both involve periopera-
tive food restriction followed by progressive weight loss [33,34]. This hypothesis also does
not explain the superiority of the glycemic control achieved after RYGB versus equivalent
weight loss from dieting [10,35].
In general, it appears that extreme caloric restriction (complete fasting or ≤ 300 kcal
per day) can result in strong short-term decreases in plasma glucose and insulin, but that
the typical dietary restrictions following RYGB surgery are not sufficient to explain the
remarkable improvements that are widely observed.
Malabsorption hypothesis
As mentioned above, RYGB has both restrictive and malabsorptive effects, both of which
are thought to be significant in achieving long-term weight loss. However, a recent study
[36] of patients undergoing long-limb RYGB found that “malabsorption accounted for
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≈ 6% and 11% of the total reduction in combustible energy absorption at 5 and 14 mo,
respectively, after this gastric bypass procedure.” In other words, malabsorptive effects are
much smaller than caloric restriction effects, and are again insufficent to account for the
immediate improvement in glucose levels and insulin sensitivity.
Ghrelin hypothesis
Ghrelin is a circulating hormone produced predominantly (90%) by P/D1 cells lining the
fundus of the human stomach. It is also produced in small amounts from the pancreas,
the intestine, the placenta, the kidney, the pituitary gland, and the hypothalamus. It is an
orexigenic hormone that stimulates appetite and food intake. Thus, ghrelin levels increase
before meals to signal hunger to the brain, specifically areas of the hypothalamic feeding
centers, which express the ghrelin receptors. The latter are also expressed by the insulin-
secreting pancreatic beta cells, a key player in glucose metabolism [37]. In addition to
its effects on feeding behavior, ghrelin has been implicated in the regulation of glucose
homeostasis [38,39]. Thus, the increase of circulating levels of ghrelin by exogenous infu-
sion of the hormone in humans results in a reduction of glucose-induced insulin secretion
and therefore glucose disposal [37]. Though the molecular mechanisms by which ghrelin
suppresses insulin secretion are not yet well understood, this observation suggests that
lower levels of ghrelin may improve the beta cell function.
According to the ghrelin hypothesis, the regulation of ghrelin may be altered by bariatric
surgery, and there are indeed studies showing that preprandial ghrelin levels are very low
after bariatric surgery. Cummings et al. were the first to report reduced levels of ghrelin
post-RYGB compared to pre-RYGB [40], and many subsequent studies have confirmed
this observation [41-43]. However, this hypothesis is still very equivocal, as other studies
have reported an increase of postprandial ghrelin levels after RYGB, while yet others have
reported no change between pre- and post-RYGB [13,19,44].Differentmethodologies and
study designs might explain these discrepancies, and more investigations are required to
fully understand the role of ghrelin in T2D remission after bariatric surgery. Diminished
ghrelin secretion would also decrease appetite and food intake, leading to weight loss on
a longer time scale than that which is relevant in the present context.
Lower intestinal hypothesis
This hypothesis, also called the hindgut hypothesis, is proposed to explain the rapid T2D
remission after RYGB and BPD via effects that result from the expedited delivery of nutri-
ents to the lower bowel after an intestinal bypass. It has attracted huge interest because
it involves active glucagon-like peptide-1 (GLP-1), an incretin which potentiates insulin
secretion and has been shown to increase proliferation and decrease apoptosis of the pan-
creatic beta cells [45], and which presents great therapeutic potential for the treatment
of T2D [46]. According to this hypothesis, the delivery of ingested nutrients to the lower
bowel increases GLP-1 release from entero-endocrine L-cells, which are found through-
out the small intestine and in high density in the ileum. In fact, a several-fold increase of
postprandial active GLP-1 secretion has been reported in a number of studies on patients
after RYGB [12,47]. The reported increases range from none to more than 5-fold in the
peak value, or more than 10-fold in the area-under-curve value, for the increase in post-
prandial GLP-1 one week after RYGB, with large error bars (up to about 70%) [48]. There
appears to be a clustering of the increases reviewed in Ref. [47] between roughly none
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and 2-fold or 3-fold, but it is natural that the results will vary with different groups of
patients and details of the procedures. We make no attempt in this paper to exclude any
published results, or to weight some results more heavily than others. However, it does
appear that the case for an increase in GLP-1 levels after RYGB is rather strong. Consis-
tent with elevated postprandial GLP-1 secretion, post-RYGB patients display an increased
incretin effect [35].
Upper intestinal hypothesis
According to this hypothesis, also called the foregut hypothesis, exclusion of a short seg-
ment of proximal small intestine (primarily the duodenum) from contact with ingested
nutrients produces direct antidiabetes effects, probably via one or more unidentified duo-
denal factors that influence glucose homoeostasis. This suggestion is supported by the
results for the duodenal-jejunal bypass (DJB) procedure, which maintains the gastric vol-
ume intact while bypassing the entire duodenum and the proximal jejunum, and which
was tested in several studies that showed an improvement in T2D with no reduction
in body weight in animals [49-52] and in obese and non-obese human patients [53,54].
Additional support for this hypothesis comes from the endoluminal duodenal sleeve pro-
cedure, where a flexible plastic sleeve is implanted in the upper intestine, causing food to
move from the stomach to the beginning of the jejunum without coming in contact with
duodenal mucosa. This technique markedly improves glucose tolerance independently of
weight loss in rats [55], pigs [56], and humans [57]. This hypothesis is, however, chal-
lenged by vertical sleeve gastrectomy, a procedure that does not result in shunting of the
duodenum and induces diabetes remission similar to gastric bypass [58-60]. It was also
shown very recently that a duodenal bypass procedure without gastric restriction did not
resolve T2D [61], in conflict with the foregut hypothesis.
Gutmicrobiota hypothesis
The gut microbiota refers to the billions of microorganisms inhabiting the mammalian
gastrointestinal tract. It performs a large number of important roles that define the physi-
ology of the host, such as immune systemmaturation, the intestinal response to epithelial
cell injury, and xenobiotic and energy metabolism. On the other side, it has been directly
implicated in the etiopathogenesis of a number of pathological states as diverse as obesity,
autism, circulatory disease, inflammatory bowel diseases, and type 1 diabetes [62,63]. The
mechanisms through which the microbiota exerts its beneficial or detrimental influences
remain largely undefined, but include elaboration of signaling molecules and recogni-
tion of bacterial epitopes by both intestinal epithelial and mucosal immune cells [62,63].
Recently, a change in the composition of the gut microbiota after gastric bypass has been
reported [64-66], which led some scientists to suggested that the rapid T2D remission
after gastric bypass may be partly due to a profound influence of the surgery on the com-
position of the gut microflora. Mechanisms that may underlie such an effect are, however,
poorly known and in need of further exploration.
Branched-chain amino acids (BCAAs) hypothesis
The concentrations of branched-chain amino acids (leucine, isoleucine, and valine) were
long known to be increased in obese individuals, compared with normal weight-, age-,
and sex-matched controls, and the increase was directly correlated with the fasting insulin
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concentration, a marker of insulin resistance [67]. In a recent prospective study involving
individuals followed for 12 years, it has been shown that individuals who had high baseline
levels of BCAAs are more prone to develop T2D, which suggests that high concentrations
of the BCAAs might be used as a biomarker to aid in diabetes risk assessment [68]. Fur-
thermore, Laferrère et al. [69] reported a significant reduction in circulating total amino
acids, especially BCAAs, after bariatric-surgery-induced weight loss, but not after dietary
intervention, suggesting that reduction in BCAAs, rather than simply weight loss, may
contribute to the rapid improvement in glucose homeostasis and the resolution of T2D
seen with gastric bypass surgery. However, a very recent study by Lindqvist and cowork-
ers [70] showed an acute elevation of BCAAs (leucine and valine) after a meal in gastric
bypass patients. More work is clearly needed to clarify the role of BCAAs.
Method
Perhaps the most common starting point in systems biology is a set of first-order ordi-
nary differential equations for the concentrations of biochemical constitutents in various
specific regions of an organism. The technique that we introduce here is meant to be
applicable to an arbitrarily large set of such equations, but is limited to “adiabatic”
(or quasi-equilibrium) states, as defined below.
Let us begin with the general set of equations
Fi = 0 with i = 1, 2, . . . ,N (1)
where Fi is a function of the molecular concentrations xk , their derivatives dnxk/dtn, the
time t, and some set of parameters rm. (Ordinarly n = 1, but the elimination of some
variables may lead to higher derivatives, as when dx/dt = a y and dy/dt = b x leads to
d2x/dt2 = a b x after y is eliminated). Let Fi → fi when all the dnxk/dtn → 0 can be
neglected:
fi = 0 (2)
in an “adiabatic” state, where the concentrations are changing slowly in comparison to the
reaction rates. The knowns in this set of equations are some concentrations (measured
or estimated) and some parameters (again measured or estimated – for example, decay
rates from half-lifes). The unknowns are the remaining parameters and concentrations.
The number of unknowns must be properly matched to the number of equations.
Let us now consider shifts in the concentrations xk resulting from shifts in the
parameters rm. Preservation of the condition fi = 0 requires that (see below)
∂ fi
∂rm
+
∑
k
∂ fi
∂xk
∂xk
∂rm
= 0 . (3)
Eq. (3) has the form∑
k
AikVk(m) = Bi(m) (4)
and this set of linear inhomogeneous algebraic equations can be numerically solved to
obtain ∂xk/∂rm. Then we can numerically integrate using
xk(r + dr) = xk(r) +
∑
m
∂xk
∂rm
drm (5)
where r stands for the set of rm.
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Eq. (3) follows from fi = 0 and fi + dfi = 0, with
dfi =
∑
m
∂ fi
∂rm
drm +
∑
k
∂ fi
∂xk
dxk . (6)
Here the rm are varied independently and the xk vary in response to maintain the steady
state, with
dxk =
∑
m
∂xk
∂rm
drm . (7)
Eq. (3) follows because the drm are independent. More generally, we can replace the
rm by other relevant variables, such as fluxes, changes in environment, or independently-
varied concentrations.
The ∂xk/∂rm are obtained at each step in the numerical integration from a numerical
solution of Eq. (3). In order for this set of algebraic equations to have a unique solution,
we need one equation (labeled by i) for each species (labeled by k). But this is the natural
way to formulate the problem from the beginning.
This paper involved no experimental research or research on humans.
Results and discussion
Specific model for immediate effect of bariatric surgery on type 2 diabetes
In constructing amodel for the effects of bariatric surgery, with an emphasis on the partic-
ularly successful technique of Roux-en-Y gastric bypass, it is important to be aware of the
enormous complexity of the biochemical and neural pathways that are affected. However,
it is also important to emphasize simplicity, because currently the details of most effects
are poorly characterized, and in many cases the reported results are even controversial
or contradictory. We are aware of only one previous model [71], which uses 10 equations
but focuses on the effect of two incretins, GLP-1 and glucose insulinotropic polypeptide
(GIP), since these two constituents are relatively well characterized. Our model is based
on a slightly less conservative approach, because it appears that the main relevant effect
of GLP-1 in the present context is increased insulin production (with the effects of GIP
being smaller and somewhat ambiguous), and that the observed declines in homeostatic
model assessment insulin resistance (HOMA-IR) following surgery [72-75] require an
additional mechanism. So, in addition to (i) the incretin effect emphasized in Ref. [71],
which corresponds to the usual version of the lower intestinal hypothesis, we add the two
basic ways in which insulin resistance might be immediately ameliorated: (ii) Some set of
substances b that induce insulin resistance might have their production diminished when
the upper part of the digestive tract is bypassed. For example, as mentioned above, there
appears to be evidence that insulin resistance may result from branched-chain amino
acids [68,69,76,77], as well as from free fatty acids. (Alternative possibilities may include
anti-incretins, ghrelin, GIP, and glucagon, whichmight have a roughly similar effect.) The
generic version of this mechanism was also considered in Ref. [71]. (iii) A different ver-
sion of the lower intestinal hypothesis, in which a postulated substance a provides an
additional insulin-independent pathway for glucose transport into skeletal muscle cells,
and its production is enhanced when digestion is diverted to the lower part of the diges-
tive tract. It has been established that muscle contraction due to exercise opens such an
insulin-independent pathway [78-81], and evidence has even been reported for insulin-
independent pathways involving nitric oxide [82], some amino acids [83], and bradykinin
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[84-86]. Of course, in addressing immediate effects of the surgery, we do not include
the many other substances that affect appetite etc. but do not appear to be of major
importance for remission after only a few days. For simplicity, we are regarding caloric
restriction, ghrelin effects, and improvements in beta cell function as primarily longer-
term than a few days, although one should bear in mind that these effects can be added
to those explicitly included in the model. Finally, we mention that the gut microbiota
hypothesis may be consistent with any of the effects in the model.
To summarize the above paragraph, we include three mechanisms for producing a
decrease in glucose levels and also insulin resistance: The first is an increase in the pro-
duction of incretins (primarily GLP-1). The second is a decrease in the production of
substances, labeled b, which contribute to insulin resistance. The third is an increase in a
substance a which provides an additional pathway for glucose to enter cells through the
plasma membrane.
Time-dependent equations
Now let us write down the equations describing the time evolution of the five molecular
concentrations xk which are regarded as most central in the regulation of the plasma
glucose level, with xG representing glucose, xI insulin, xi incretins (with emphasis onGLP-
1), xb substances which increase insulin resistance, and xa a substance which opens an
insulin-independent pathway for glucose transport. The model is defined by
dxG
dt = RG − rGIxGxIe
−αbxb − rGaxGxa − rGxG (8)
dxI
dt = rIGxG + rIixGxi − rIxI (9)
dxi
dt = r Ri − rixi (10)
dxa
dt = r Ra − raxa (11)
dxb
dt = (rmax − r) Rb − rbxb . (12)
In Eq. (8), RG is the rate at which glucose is received by the plasma from digestion; rGI
gives the rate at which insulin stimulates glucose transport in the absence of the “bad”
substances b; e−αbxb is a factor representing the contribution of b to insulin resistance;
and rGa determines the rate at which the postulated “good” substance a stimulates glu-
cose transport via an alternative pathway. (RG is actually the rate at which glucose is
made available to the cells which normally absorb glucose via an insulin-dependent path-
way, and which are therefore relevant in the present context – e.g., skeletal muscle cells.)
In Eqs. (8)-(12), the final terms represent “natural disappearance”. (The degradation of
incretins by dipeptidyl-peptidase 4 (DPP4) is thus not explicitly exhibited.) In Eq. (9), rIG
gives the rate at which glucose stimulates insulin production (in the pancreas), and rIi
represents the enhancement by incretins. In Eq. (10), the production of incretins (stimu-
lated by glucose in the intestine) is increased by a factor r, with a pre-surgery value r = 1
and a post-surgery value r = rmax. Finally, in Eqs. (11) and (12), rRa and (rmax − r)Rb
are respectively the input of substances a and b from digestion, with the same scaling
assumed as for the incretins.
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Equations in an “adiabatic” postprandial state
Let us now consider an “adiabatic” state in which the concentrations are slowly varying
(e.g. on a time scale∼ hours, with a time scale for relevant reactions typically∼ minutes).
In the present context, we are concerned with postprandial states, since these are themost
important in relation to glucose homeostasis. (In the fasting state, with glucose secreted
from the liver rather than intestine, there would be essentially no production of incretins,
and Eqs. (10)-(12) would be invalid.) There is, of course, a continuous evolution up to and
down from the peak concentrations of glucose, insulin, GLP-1, etc. following ingestion,
but in the model these concentrations are taken to evolve together. The scaled values
which are used here may therefore apply at any point (over a period of several hours), and
when integrated over time they also apply to the “area under curve” or average values of
the concentrations.
With time derivatives neglected, the linear equations are trivially solved:
xi = r Riri (13)
xa = r Rara (14)
xb = (rmax − r) Rbrb . (15)
xI = 1rI
(
rIG + rIir Riri
)
xG . (16)
Substitution into the equation for xG then results in a quadratic equation. One can
easily obtain the explicit solution for xG in the present case, but it is clear that this
approach does not readily generalize to problems where one can have a very large num-
ber of coupled equations. This fact is what motivates the general method described in
the preceding section, in which the parameters rm are treated mathematically as con-
tinuous variables. According to Eq. (3), the solution for the derivatives ∂xk/∂rm is a
linear algebraic problem. This problem, and the subsequent integration with respect to
the rm, can then be solved with standard numerical methods. An additional advantage
is that some parameters may disappear when the derivatives are taken – for example,
RG in Eq. (8).
Effect of surgery treated as a continuous variable
Using this approach (with r regarded as a continuous variable) one obtains
dxi
dr =
Ri
ri
(17)
dxa
dr =
Ra
ra
(18)
dxb
dr = −
Rb
rb
(19)
dxI
dr =
( rIG
rI
+ rIi RirI ri r
) dxG
dr +
rIiRi
rI ri
xG . (20)
These are mathematical equations, but one can imagine a thought experiment in which
these equations, and those below for xG, describe the rates at which concentrations of
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chemical species change as more and more of the upper digestive tract is bypassed.
Applying d/dr to the condition (from Eq. (8))
−RG + rGIxGxIe−αbxb + rGaxGxa + rGxG = 0 (21)
then leads finally to the following equation for glucose alone:
dxG
dr = −
aieαr x2G + α (aI + air ) eαr x2G + aaxG
2 (aI + air ) eαr xG + aar + rG (22)
where
aI = rGIrIGrI e
−αrmax , ai = rGIrIiRirI ri e
−αrmax (23)
α = αb Rbrb , aa = rGa
Ra
ra
. (24)
Here aI , ai, α, and a1 respectively represent the strengths of the glucose-insulin-
glucose interaction (i.e., insulin-stimulated glucose transport into cells), glucose-insulin-
incretin-glucose interaction (i.e., the enhancement by incretins), insulin resistance due
to substances b, and direct glucose transport due to substance a. We can scale these
strengths by dividing numerator and denominator by the strength aI of the usual insulin
mechanism:
dxG
dr = −
cieαr x2G + α (1 + ci r) eαr x2G + caxG
2 (1 + cir) eαr xG + car + cG (25)
with
ci = ai/aI = rIiRirIGri , ca = aa/aI , cG = rG/aI . (26)
We also scale the glucose concentration (along with the parameters) so that xG = 1 for
r = 1.
Test of incretin hypothesis
The most common hypothesis to explain type 2 diabetes remission immediately after
surgery is that it is due solely to a large enhancement of (active) GLP-1 production in the
lower intestine, with a nice review of the many studies in this area by Rhee et al. [47].
We now set out to test this hypothesis. The measured enhancements of active GLP-1
range from none (or a slight decrease) to more than 10-fold [47,48], with the majority of
reported values being well below 10, and in fact  2 or 3 [47], so we will show the results
for
1 ≤ r ≤ 10 . (27)
Of course, one expects variations among different groups of patients, and with different
postoperative restrictions. It should also be mentioned that there are different forms of
GLP-1, and that the half-life of active GLP-1 in circulation is less than 2 minutes.
The normal contribution of incretins (mainly GLP-1) to insulin secretion is usually
considered to be of the order of 50 − 70% [87,88]. As can be seen from Eqs. (9), (13)
(with r = 1), (23), and (26),
1 ≤ ci ≤ 2 (28)
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corresponds to the incretin contribution to insulin secretion lying between 50% and 67%.
But we will also include the case of 100% (implying that there would be no insulin pro-
duction whatsoever without the assistance of incretins), which is given by aI = 0 in
Eq. (22), or
1 + ci r → ci r (29)
in Eq. (25).
In Figure 1, results are shown for the above hypothesis, that the immediate effects
of surgery are due entirely to increased incretin production, and for essentially the full
range of values consistent with experiment. The three lower curves in Figure 1 show the
decline in glucose concentration for up to a 10-fold increase in incretin production, and
the horizontal line at the top shows the corresponding result for glucose × insulin, or
xG × xI , which is a measure of insulin resistance analogous to homeostatic model assess-
ment insulin resistance (HOMA-IR) measured in the fasting state. The higher two of the
descending curves correspond to ci = 1 and 2 in Eq. (25), with no contribution from
substances other than incretins:
dxG
dr = −
cixG
2 (1 + cir) . (30)
The lowest curve corresponds to the upper bound that 100% of insulin secretion is due
to incretins, and it will also be discussed below.
Here we have omitted the term cG in the denominator, which correponds to the “natural
disappearance” of glucose through excretion. This means that we are overestimating the
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Figure 1 Effect of incretin concentration alone. Two tests of the hypothesis that an increase in incretin
concentration alone can explain the fall in glucose level and homeostatic model assessment insulin
resistance (HOMA-IR) immediately after surgery. The three lower curves show the scaled glucose
concentration xG as a function of the factor r by which active incretins are increased. (Reported values of r
range from 1 to more than 10, with most 2 or 3.) These curves correspond to three assumptions regarding
the incretin contribution to insulin production: 50% for the top curve, 67% for the middle curve, and 100% for
the bottom curve. Even in the most favorable scenarios, the decrease is insufficient to explain all the
observations. The horizontal line at the top is the scaled product glucose × insulin, or xG × xI , which is a
measure of insulin resistance analogous to HOMA-IR. As found in Eq. (33), it is constant for all scenarios – i.e.,
for all values of r and all percentages for the incretin contribution. In other words, the incretin mechanism
alone predicts no decrease whatsoever in this quantity. Many observations, on the other hand, show a very
substantial drop in HOMA-IR immediately or very soon after surgery.
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decline in glucose as a function of r, since omission of cG in the denominator increases
the magnitude of the negative derivative. The lowest curve in the figures are therefore
extreme lower bounds on howmuch the glucose level and the glucose×insulin can decline
if only incretins are involved, and if 10 is taken to be the upper bound on r.
The solution to Eq. (30) is
xG =
( 1 + ci
1 + cir
)1/2
. (31)
It can be substituted into Eq. (16), which becomes
xI = 1 + cir1 + ci xG (32)
after the insulin concentration (along with the parameters) is scaled to make xI = 1 for
r = 1. It follows that
glucose × insulin = 1 + cir1 + ci x
2
G = 1 . (33)
Therefore, in every scenario for glucose reduction being produced entirely by incretins,
there is no drop whatsoever in glucose × insulin, a quantity which is the analog in a
postprandial state of HOMA-IR. The observations show, on the other hand, that HOMA-
IR typically drops immediately after surgery [72-75], e.g. by 50% after one week in both
obese subjects with T2D and matched subjects with normal glucose tolerance [48].
Again, the lowest curve in Figure 1 corresponds to the upper bound that incretins
account for 100% of insulin secretion. In this case, according to Eq. (29), Eq. (31) reduces
to
xG = 1r1/2 . (34)
The most extreme limit of possible scenarios thus gives a drop in glucose concentration
of about 1/
√
10 ≈ 0.32, but more commonly reported values of r and ci give drops of
about 0.7 − 1.0, as can be seen in Figure 1. On the other hand, some observations show
much stronger decreases soon after surgery – e.g., a drop by a factor of 0.31 (from 495
mg/dL to 153 mg/dL) in 14 days [10]. The expected long-term recovery of β-cells seems
unlikely to produce such a large decrease so quickly, and in other cases there are large
drops in as little as 3 days.
There are two qualitative reasons for the above results: (i) The incretins are effective
in increasing the insulin concentration, but not the insulin sensitivity of the cells. (ii)
The effect of the incretins is second-order in the glucose concentration, as can be seen
in Eq. (25). In other words, as the glucose concentration falls, the insulin concentra-
tion also falls, with the rate of glucose absorption being proportional to the product of
these concentrations. On the other hand, the postulated substance a would have an effect
that is first-order, because it directly stimulates glucose transport without insulin as an
intermediary.
In summary, our results indicate that the most plausible values for an increase in GLP-1
can largely, but not completely, explain the observed beneficial changes immediately after
surgery. Let us now turn to the other possibilities, considering each separately.
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Test of branched-chain amino acids hypothesis (and other foregut hypotheses)
First consider the effect of only relieving the extra insulin resistance due to substances b,
by setting ci = ca = 0 (and cG = 0) in Eq. (25), so that dxG/dr = −αxG/2 and
xG = e−αr/2 . (35)
If αrmax/2 is substantial, then the glucose concentration will undergo a substantial drop.
This fact lends some credibility to the branched-chain amino acids hypothesis discussed
above [68,69,76,77], even though insulin resistance is more commonly attributed to the
release of lipids from adipose tissue.
These results actually have more general validity, since this same model can be applied
to any factor from the stomach or upper intestine (duodenum and jejunum) that induces
insulin resistance.
Possibility of alternative insulin-independentpathway for transport of glucose into muscle
cells
Finally consider the effect of increasing only the influence of the postulated substance a,
which opens an alternative pathway, by setting ci = α = 0 (and again cG = 0). Eq. (25)
becomes
dxG
dr = −
caxG
2xG + car . (36)
The results are shown in Figure 2. Since the insulin level does not change in this case, the
same curve describes glucose × insulin. In the limiting case of extreme insulin resistance,
with aI = 0 in Eq. (22), Eq. (25) reduces to
dxG
dr = −
xG
r (37)
so
xG = 1r . (38)
A substance opening a new pathway could thus have a strong effect if it were produced
in appreciable abundance.
In the limiting cases, the 1/r decrease of Eq. (38), in both glucose level and glucose ×
insulin, represents a first-order effect. On the other hand, the 1/r1/2 decrease of Eq. (34)
in glucose level, with no drop of glucose × insulin in Eq. (33), represents a second-order
effect, as defined below Eq. (34). This is a simple way of understanding why an insulin-
independent pathway would be so effective in reducing both glucose and glucose ×
insulin.
Conclusions
Our general method was employed in a simple model of the response of plasma
glucose concentration to bariatric surgery (with the paradigm being Roux-en-Y gas-
tric bypass). This model includes three mechanisms that might be responsible for the
remarkable positive effect observed for most patients immediately following surgery,
before any appreciable weight loss. The first mechanism is the one which is cur-
rently the most widely embraced: increased production of incretins (mainly GLP-1).
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Figure 2 Effect of alternative insulin-independent pathway. Glucose concentration xG as a function of
the increase r in a substance a which opens an alternative insulin-independent pathway for glucose
absorption (by the cells which are relevant in the present context). The top and middle curves are
respectively for ca = 1 and 2, where ca is the strength of this alternative pathway relative to the normal
insulin-dependent pathway in a patient with strong insulin resistance. The bottom curve represents the limit
of extreme insulin resistance. The scaled product glucose × insulin is given by exactly these same curves,
since the insulin level is constant in this case. If the present mechanism and that of Figure 1 are both
operative, there is, of course, an even larger drop in glucose level, and also a substantial drop in glucose ×
insulin. This product, in a postprandial state, is a measure of insulin resistance analogous to HOMA-IR – which
is the same product measured in the fasting state.
We performed calculations up to and including the most favorable scenario, in which
there is about a 10-fold increase in the incretins and the incretins account for 100%
of insulin secretion. The results, shown in Figure 1, indicate that the most plausible
values for an increase in GLP-1 alone cannot fully account for the decreases in glu-
cose level which have been reported, or the large and rapid observed decreases in
HOMA-IR.
In other words, we find that GLP-1 can largely, but not completely, explain the observed
beneficial changes immediately after surgery.
Another possiblemechanism, involving insulin resistancewhich is diminishedwhen the
stomach and upper intestine are bypassed, could be effective if this were indeed the main
cause of type 2 diabetes in the present context. However, for obese patients undergoing
bariatric surgery, the cause of insulin resistance is more commonly thought to be the
release of fatty acids from fatty tissue, which will decrease only after appreciable weight
loss.
This leaves the possibility that diversion of food to the lower intestine results in the
production of a substance which opens an alternative insulin-independent pathway for
transport of glucose into cells. As mentioned above, it has been established that exercise
opens an insulin-independent pathway [78-81], involving an alternative pool of intracel-
lular GLUT-4 which activates glucose transport through the cell membrane, and it has
been argued that there are additional insulin-independent pathways involving nitric oxide
[82], some amino acids [83], and bradykinin [84-86], so there are precedents for such a
mechanism.
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The results of Figure 2 demonstrate that this would be a quite robust mecha-
nism, which would produce large decreases in both plasma glucose and the product
glucose × insulin, which provides a measure of insulin resistance analogous to
HOMA-IR. If such a substance could be detected, it might, of course, be relevant to
pharmaceutical approaches.
In summary, the present results suggest that another possible mechanism should be
added to the current list of potential explanations for immediate glycemia normalization
following Roux-en-Y gastric bypass surgery: enhanced production in the lower intestine
of a substance which opens an alternative insulin-independent pathway for glucose
transport.
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